GSK, Spero in Exclusive License Agreement for Late-Stage Antibiotic Asset

 

• The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries
• Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties.
• GSK to purchase $9 million in shares of Spero common stock

https://www.biospace.com/article/releases/gsk-and-spero-therapeutics-announce-exclusive-license-agreement-for-late-stage-antibiotic-asset-tebipenem-hbr/